Marino Garcia - Sep 30, 2025 Form 4 Insider Report for Dianthus Therapeutics, Inc. /DE/ (DNTH)

Role
CEO AND PRESIDENT, Director
Signature
/s/ Adam Veness, as attorney-in-fact for Marino Garcia
Stock symbol
DNTH
Transactions as of
Sep 30, 2025
Transactions value $
$0
Form type
4
Date filed
10/3/2025, 07:00 PM
Previous filing
Feb 4, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Garcia Marino CEO AND PRESIDENT, Director C/O DIANTHUS THERAPEUTICS, INC., 7 TIMES SQUARE, 43RD FLOOR, NEW YORK /s/ Adam Veness, as attorney-in-fact for Marino Garcia 2025-10-03 0001669866

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DNTH Stock Option (Right to Buy) Award $0 +120K $0.00 120K Sep 30, 2025 Common Stock 120K $39.35 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares of common stock underlying this stock option award will vest in equal monthly installments over the four years after September 30, 2025, subject to the Reporting Person's continued service to the Issuer on each such vesting date.